Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;326:1205-1207 (31 May), doi:10.1136/bmj.326.7400.1205
Bob Burton, freelance journalist1, Andy Rowell, freelance journalist2
1 POBox 157, O'Connor, ACT2602, Australia bobburton@ozemail.com.au, 2 Devon TQ10 9JL
Public relations companies are experts at "third party technique"helping the drug industry separate the message from what could be seen as a self interested messenger. But most journalists have a sketchy idea about how the public relations industry works, and thereby are vulnerable to uncritically accepting the disguised messages of the drug industry
| The first 150 words of the full text of this article appear below. |
Few doctors have heard of the world's leading medical public relations companiesEdelman, Ruder Finn, Noonan/Russo Presence, the Shire Health Group, and Medical Action Communications, among others. Yet barely a day passes without most doctors or their patients being exposed to messages that have been carefully crafted by these public relations companies, aimed at boosting sales of their clients' drugs.
|
According to the public relations industry's trade press, the top five companies in "healthcare PR" raked in over $300m (£186m, ##260m) last year for everything from planning pre-launch media coverage of new drugs and cultivating doctors to publishing medical journals and wooing patients' groups.
At the heart of most public relations strategies is what is referred to as
the "third party technique." Edelman's associate director health
in London, Paul Keirnan, explained the technique as separating the message
from what could be seen as a self interested messenger. A pharmaceutical
company defending
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses